Literature DB >> 23142060

Abiraterone acetate: a hat trick of clinical benefits.

Michael T Schweizer1, Emmanuel S Antonarakis.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2012        PMID： 23142060      PMCID： PMC4014059          DOI： 10.1016/S1470-2045(12)70460-6

Source DB:  PubMed          Journal:  Lancet Oncol        ISSN： 1470-2045            Impact factor:   41.316


× No keyword cloud information.
  9 in total

1.  Sipuleucel-T immunotherapy for castration-resistant prostate cancer.

Authors:  Philip W Kantoff; Celestia S Higano; Neal D Shore; E Roy Berger; Eric J Small; David F Penson; Charles H Redfern; Anna C Ferrari; Robert Dreicer; Robert B Sims; Yi Xu; Mark W Frohlich; Paul F Schellhammer
Journal:  N Engl J Med       Date:  2010-07-29       Impact factor: 91.245

2.  Effect of abiraterone acetate and prednisone compared with placebo and prednisone on pain control and skeletal-related events in patients with metastatic castration-resistant prostate cancer: exploratory analysis of data from the COU-AA-301 randomised trial.

Authors:  Christopher J Logothetis; Ethan Basch; Arturo Molina; Karim Fizazi; Scott A North; Kim N Chi; Robert J Jones; Oscar B Goodman; Paul N Mainwaring; Cora N Sternberg; Eleni Efstathiou; Dennis D Gagnon; Margaret Rothman; Yanni Hao; Cameron S Liu; Thian S Kheoh; Christopher M Haqq; Howard I Scher; Johann S de Bono
Journal:  Lancet Oncol       Date:  2012-11-09       Impact factor: 41.316

3.  Denosumab versus zoledronic acid for treatment of bone metastases in men with castration-resistant prostate cancer: a randomised, double-blind study.

Authors:  Karim Fizazi; Michael Carducci; Matthew Smith; Ronaldo Damião; Janet Brown; Lawrence Karsh; Piotr Milecki; Neal Shore; Michael Rader; Huei Wang; Qi Jiang; Sylvia Tadros; Roger Dansey; Carsten Goessl
Journal:  Lancet       Date:  2011-02-25       Impact factor: 79.321

4.  Increased survival with enzalutamide in prostate cancer after chemotherapy.

Authors:  Howard I Scher; Karim Fizazi; Fred Saad; Mary-Ellen Taplin; Cora N Sternberg; Kurt Miller; Ronald de Wit; Peter Mulders; Kim N Chi; Neal D Shore; Andrew J Armstrong; Thomas W Flaig; Aude Fléchon; Paul Mainwaring; Mark Fleming; John D Hainsworth; Mohammad Hirmand; Bryan Selby; Lynn Seely; Johann S de Bono
Journal:  N Engl J Med       Date:  2012-08-15       Impact factor: 91.245

5.  Prednisone plus cabazitaxel or mitoxantrone for metastatic castration-resistant prostate cancer progressing after docetaxel treatment: a randomised open-label trial.

Authors:  Johann Sebastian de Bono; Stephane Oudard; Mustafa Ozguroglu; Steinbjørn Hansen; Jean-Pascal Machiels; Ivo Kocak; Gwenaëlle Gravis; Istvan Bodrogi; Mary J Mackenzie; Liji Shen; Martin Roessner; Sunil Gupta; A Oliver Sartor
Journal:  Lancet       Date:  2010-10-02       Impact factor: 79.321

6.  Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer.

Authors:  Ian F Tannock; Ronald de Wit; William R Berry; Jozsef Horti; Anna Pluzanska; Kim N Chi; Stephane Oudard; Christine Théodore; Nicholas D James; Ingela Turesson; Mark A Rosenthal; Mario A Eisenberger
Journal:  N Engl J Med       Date:  2004-10-07       Impact factor: 91.245

7.  A randomized, double-blind, dose-finding, multicenter, phase 2 study of radium chloride (Ra 223) in patients with bone metastases and castration-resistant prostate cancer.

Authors:  Christopher C Parker; Sarah Pascoe; Aleš Chodacki; Joe M O'Sullivan; Josep R Germá; Charles Gillies O'Bryan-Tear; Trond Haider; Peter Hoskin
Journal:  Eur Urol       Date:  2012-09-13       Impact factor: 20.096

8.  Long-term efficacy of zoledronic acid for the prevention of skeletal complications in patients with metastatic hormone-refractory prostate cancer.

Authors:  Fred Saad; Donald M Gleason; Robin Murray; Simon Tchekmedyian; Peter Venner; Louis Lacombe; Joseph L Chin; Jeferson J Vinholes; J Allen Goas; Ming Zheng
Journal:  J Natl Cancer Inst       Date:  2004-06-02       Impact factor: 13.506

9.  What is the real impact of bone pain on survival in patients with metastatic hormone-refractory prostate cancer treated with docetaxel?

Authors:  Stéphane Oudard; Eugeniu Banu; Jacques Medioni; Florian Scotte; Adela Banu; Eric Levy; Johana Wasserman; Gabriel Kacso; Jean-Marie Andrieu
Journal:  BJU Int       Date:  2009-02-06       Impact factor: 5.588
  9 in total
  1 in total

1.  Clinical Evaluation of Abiraterone in the Treatment of Metastatic Prostate Cancer.

Authors:  Jatinder Goyal; Emmanuel S Antonarakis
Journal:  Clin Med Insights Urol       Date:  2013-07-10
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.